Skip to content
‹ Back to IndustriesSciences

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · · Fairjourney BioAntibody DiscoveryDevelopabilityCmc
Share
Listen to the audio brief

Key facts, context, and what it means.

AUDIO
0:00—
Antibody developability checks are moving into discovery instead of waiting for development

Key takeaways

01

Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Maria Gonzalez-Pajuelo, cofounder and executive vice president of technology and scientific office at FairJourney Bio, says that order is changing. She told Drug Discovery News, in a Sept. 30 piece by Bree Foster, that developability now carries far more weight during discovery itself instead of being saved for later-stage development. Her reasoning is blunt: a functional antibody that can't be manufactured and given to patients doesn't help anyone.

That moves a decision earlier in the program.

Where a strong binder turns into a repair job

A discovery campaign can produce hundreds or thousands of molecules that recognize a target, and teams narrow the pool on affinity, specificity and biological function. Nothing in that funnel guarantees the winner will be easy to develop. A molecule can perform very well in assays and still have poor stability, low expression, aggregation or formulation trouble.

Found late, those problems turn a promising lead into an engineering project: the team modifies the molecule and redoes work before the program can move again. Found early, the same information lets the team switch to a sibling molecule with a cleaner profile, or fix the problem while it's still cheap. Gonzalez-Pajuelo described the goal as discovery handing CMC something it can take forward easily. Skip that step, she said, and developability becomes the bottleneck.

What's changing is when properties such as stability and solubility get checked.

Developability is the set of physical and chemical properties that decide whether an antibody can be produced consistently and formulated for how it will be given. CMC (chemistry, manufacturing and controls) is the development workstream that has traditionally tested them, usually after a lead was already chosen.

Choosing the discovery method from the end product

The same focus on the finished drug now reaches back to how antibodies are found in the first place. Discovery teams can pick from a broad set of in vivo and in vitro tools: hybridoma technology, transgenic animals, and phage, yeast and mammalian display. Each has different strengths. Gonzalez-Pajuelo's view is that no single strategy fits every case. Having access to all of them matters less than knowing which one suits a given target, and that depends on the target's biology and the target product profile.

The target product profile sets out what the finished therapy needs: how it works, how it will be given and what properties manufacturing will require.

When scoping a discovery partner, ask which method they would use against this specific target and how the target product profile, including route of administration, drove that choice. A partner that offers every platform should still be able to explain why one of them fits.

Bigger screening panels made early checks practical

Moving these checks earlier depends on assays that can cope with the volumes seen in discovery. Genetic Engineering and Biotechnology News reported in September 2018 on comments from Jennifer F. Nemeth, director of biophysics, structural characterization at Janssen Research & Development. She said that a decade earlier, many assays had lower throughput and could take only 2, 10 antibodies at a time. Teams were now running multiple panels of tens to hundreds of antibodies through a single assay, she said, and these higher-throughput assays had moved earlier into drug discovery. One example was a high-throughput mass profiling workflow that Janssen R&D was developing with Genedata on Genedata's Biologics Refiner software.

Throughput rose while targets stayed scarce

2, 10
Antibodies a typical characterization assay handled about a decade before 2018
10s, 100s
Antibodies per assay panel Janssen R&D was running by 2018
5.3
New drug targets identified per year, per a 2006 analysis GenScript's Liusong Yin cited
324
Distinct molecular targets behind all drugs with a known mode of action in that 2006 paper

Genetic Engineering and Biotechnology News (2018), citing a 2006 analysis

Liusong Yin, director of antibody services at GenScript, said a fast-growing pool of candidates was chasing a slow-growing pool of targets, with most antibody campaigns aimed at existing targets. Citing regulatory trends in the European Union, Nemeth said a molecule that merely matches a product already approved may not necessarily win acceptance from the European Medicines Agency. Yin's broader point was that risk builds up: anything not dealt with at one stage costs more at the next.

When several programs pursue existing targets, the properties that make a molecule easier to manufacture and administer could be where one program pulls ahead of another.

Nemeth also separated the two stages. Discovery, she said, involves examining many different antibodies once or twice each, while development concentrates on several lots of a single antibody. That suggests a discovery-stage developability screen and development work answer different questions. For teams moving checks earlier, the payoff could be fewer surprises in development rather than less development work.

Immunogenicity shows up in patients, and then on the label

Not every property that matters can be ranked in a discovery screen, and some only show up in patients. A 2020 review in Frontiers in Immunology by Anna Vaisman-Mentesh, Yariv Wine and colleagues at Tel Aviv University and the University of Kansas found that some monoclonal antibodies trigger anti-drug antibodies in up to 70% of patients. Those anti-drug antibodies can change a drug's pharmacokinetics and pharmacodynamics, lower its efficacy or neutralize it altogether. They are also hard to detect: because the analyte and the antigen are both antibodies, the authors described most assays as cumbersome, costly, slow and poorly standardized. The review also summarized engineering approaches meant to make antibodies less likely to provoke this response.

Writing in Frontiers in Immunology in 2024, Steven Swanson of Genentech described FDA draft guidance that asks companies to describe clinically significant anti-drug antibodies in product labels, in addition to reporting how often they occur. Clinical significance depends on effects on pharmacokinetics, pharmacodynamics, efficacy or safety, and the guidance also specifies where that information goes in the label.

Swanson also offers the counterweight. In many cases, he notes, the immune response to a protein therapeutic has no clinical significance at all. An anti-drug antibody signal is something to understand and characterize. It is not automatically a reason to drop a program.

AI-designed antibodies face the same question

Those design tools face the same problem Gonzalez-Pajuelo describes. For R&D leaders evaluating these platforms, the thing to watch is whether stability, solubility and expression are scored alongside affinity at the design step, or whether developability is still something someone checks afterward.

Featured companies

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, SR-Tiget's family programme coordinated 133 follow-up visits against 17 new treatments. That gap keeps widening because each patient enters roughly 15 years of twice-yearly checkups.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—on limits

Two photonic AI components reach outside testers—on limits

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly’s Goochland County site is designed to make APIs and finished medicines on one campus. Virginia Business reported the first building is expected to open in 2030.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

MG
Maria Gonzalez-Pajuelo

FairJourney Bio

Maria Gonzalez-Pajuelo discusses the significance of considering developability early in the antibody discovery process.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512